ストックスクリーナーアプリを入手
67.47
4.78%
3.08
前日終値:
$64.39
開ける：
$66.56
24時間の取引高:
128.10K
Relative Volume:
0.75
時価総額：
$451.99M
収益：
-
当期純損益:
$-14.99M
株価収益率:
-32.65
EPS:
-2.0665
ネットキャッシュフロー:
$-10.01M
1週間 パフォーマンス:
+14.17%
1か月 パフォーマンス:
+19.95%
6か月 パフォーマンス:
+2.24%
1年 パフォーマンス:
+104.45%
1日の値動き範囲:
$65.00
$67.90
1週間の範囲:
$59.06
$67.90
52週間の値動き範囲:
$29.18
$105.00
Monopar Therapeutics Inc Stock (MNPR) Company Profile
名前
Monopar Therapeutics Inc
セクター
電話
(847) 388-0349
住所
1000 SKOKIE BLVD SUITE 350, WILMETTE
Compare MNPR vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MNPR
Monopar Therapeutics Inc
|
67.47 | 451.99M | 0 | -14.99M | -10.01M | -2.0665 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-09 | 開始されました | Morgan Stanley | Overweight |
| 2025-11-14 | ダウングレード | Raymond James | Strong Buy → Outperform |
| 2025-11-10 | 開始されました | Leerink Partners | Outperform |
| 2025-10-13 | 開始されました | Barclays | Overweight |
| 2025-09-09 | 開始されました | BTIG Research | Buy |
| 2025-09-03 | 開始されました | Oppenheimer | Outperform |
| 2025-09-03 | 開始されました | Raymond James | Strong Buy |
| 2025-08-26 | 再開されました | H.C. Wainwright | Buy |
| 2025-07-07 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-06-23 | 開始されました | Chardan Capital Markets | Buy |
| 2025-03-19 | 再開されました | Piper Sandler | Overweight |
| 2025-01-10 | 開始されました | Piper Sandler | Overweight |
| 2024-10-11 | 開始されました | Rodman & Renshaw | Buy |
| 2021-01-28 | 開始されました | ROTH Capital | Buy |
すべてを表示
Monopar Therapeutics Inc (MNPR) 最新ニュース
1IY0 Forecast — Price Target — Prediction for 2027 - TradingView
Operating income of Monopar Therapeutics Inc – DUS:1IY0 - TradingView
Monopar Therapeutics stock gains 3.15% as price finishes near session high - Traders Union
Basic earnings per share (basic EPS) of Monopar Therapeutics Inc – DUS:1IY0 - TradingView
Monopar Therapeutics StockThursday chart and volatility snapshot - AD HOC NEWS
Monopar Therapeutics Inc (MNPR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Monopar Therapeutics Inc (MNPR) Institutional Confidence - TradingKey
Monopar Therapeutics Inc (MNPR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Monopar Therapeutics Inc (MNPR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Monopar Therapeutics Inc (MNPR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Monopar Therapeutics Inc (MNPR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Why is Monopar Therapeutics stock up today? - Traders Union
Monopar Therapeutics Inc (MNPR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Monopar Therapeutics Inc (MNPR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Monopar Therapeutics Inc (MNPR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Monopar Therapeutics stock price forecast: $66.1636 resistance in focus as MNPR climbs 3.12% - Traders Union
Wall Street Analysts Believe Monopar Therapeutics (MNPR) Could Rally 88.92%: Here's is How to Trade - Zacks Investment Research
Monopar Therapeutics Q1 2026 Earnings: Smaller-than-Expected Loss as EPS Surprises PositivelyRevenue Report - newsline.com
Understanding Momentum Shifts in (MNPR) - Stock Traders Daily
Monopar Therapeutics (MNPR) Climbs Nearly 2%, Approaches Key Resistance at $63.64Inside Day Breakout - newsline.com
Piper Sandler Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Maintains Target Price $101 - Moomoo
Monopar Therapeutics Inc (MNPR) Receives a Buy from Piper Sandler - The Globe and Mail
Monopar Therapeutics stock declines as late-session selling erases earlier gains - Traders Union
Monopar: Buy Rating Reiterated as ALXN1840 Data Underpin Valuation and $104 Price Target Maintained - TipRanks
Lake Street Keeps Their Buy Rating on Monopar Therapeutics Inc (MNPR) - The Globe and Mail
A Quick Look at Today's Ratings for Monopar Therapeutics(MNPR.US), With a Forecast Between $101 to $105 - Moomoo
MNPR Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost DisciplineFinal Results - newsline.com
MNPR Stock Price, Quote & Chart | MONOPAR THERAPEUTICS INC (NASDAQ:MNPR) - ChartMill
Monopar Therapeutics (MNPR) Showcases Promising Phase 2 Results at EASL Congress 2026 - GuruFocus
Monopar presents phase 2 data on Wilson disease treatment - Investing.com UK
Monopar Therapeutics Presents Phase 2 Data for ALXN1840 at EASL Congress 2026, Demonstrating Liver Disease Stabilization and Neurological Improvements in Wilson Disease Patients - Quiver Quantitative
Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026 - GlobeNewswire Inc.
Monopar Therapeutics Presents Phase 2 Results of ALXN1840 (Tiomolibdate Choline) for Wilson Disease at EASL International Liver Congress 2026 7 - Minichart
MNPR Q1 2026 Earnings: Loss Narrower Than Expected, Stock Rises on Positive SurpriseEarnings Recovery Stocks - newsline.com
MNPR Q1 2026 Earnings: Narrower-than-expected loss as early-stage biotech advances radiopharmaceutical pipelineRevenue Report - newsline.com
Avoiding Lag: Real-Time Signals in (MNPR) Movement - Stock Traders Daily
Monopar Highlights Phase 2 ALXN1840 Data in Wilson Disease - TipRanks
Monopar Therapeutics (MNPR) shares Phase 2 Wilson disease data at EASL 2026 - Stock Titan
Monopar Therapeutics shares dip amid rising selling pressure - Traders Union
Monopar Therapeutics (MNPR) Holds Steady at $64.43: Slight Decline Signals ConsolidationLast Point Resistance - The Legal Advocate
What triggered Monopar Therapeutics shares' latest price surge - Traders Union
Monopar Therapeutics stock rises as short-term exhaustion signals surface after recent rally - Traders Union
What triggered Monopar Therapeutics shares' latest price pullback - Traders Union
Monopar Therapeutics (MNPR) News Today: Latest Market and Industry Updates - Traders Union
Monopar Therapeutics stock price forecast: Holding $60.25 support as MNPR declines 2.47% - Traders Union
Monopar Therapeutics Q1 2026 Earnings: Narrower Loss Surprises MarketEarnings Outlook Update - Newser
MNPR Q1 2026 Earnings: Surprise EPS Beat in Pre-Revenue BiotechRevenue Inflection Point - The Legal Advocate
Monopar Therapeutics Presents Positive Phase 2 Results for ALXN1840 in Wilson Disease Patients - Minichart
Monopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease - The Manila Times
Monopar reports positive Wilson disease trial data publication By Investing.com - Investing.com South Africa
Monopar Showcases ALXN1840 Phase 2 Wilson Disease Data - TipRanks
Monopar Therapeutics Inc (MNPR) 財務データ
収益
当期純利益
現金流量
EPS
0.74%
1.44%
大文字化:
|
ボリューム (24 時間):